Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma
Third-line systemic therapy following ICI combinations and sequential VEGFR-TKIs shows feasible clinical effectiveness and manageable toxicity in real-world patients with advanced RCC.
Authors
- T. Takagi
- Hiroaki Shimmura
- Shinsuke Mizoguchi
- Kazuhiko Yoshida
- Yasunobu Hashimoto
- Koichi Nishimura
- Hironori Fukuda
- Junpei Iizuka
- Yuki Nemoto
- Takayuki Nakayama
- Tsunenori Kondo
- Hiroki Ishihara
Institutions
- Kawaguchi Junior College (JP)
- Jyoban Hospital of Tokiwa Foundation (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Tokyo Women's Medical University (JP)
- Noguchi Hospital (JP)
- Saiseikai Ibaraki Hospital (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1093/jjco/hyag037
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00